Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7315-7319

  Zhang, Mei Xiang ^a,c   Xu, Yi Jun ^b   Zhu, Ming Chen ^a   Yan, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Esophageal squamous cell carcinoma; Immunohistochemistry; OPN c

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ESOPHAGUS TUMOR; FEMALE; FOLLOW UP; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893423973     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7315     Document Type: Article

References (24)

1. Agrawal D, Chen T, Irby R, et al (2002). Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Ins, 94, 513-21.
2. Barry ST, Ludbrook SB, Murrison E, et al (2000). Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res, 258, 342-51.
3. Chambers AF, Wilson SM, Kerkvliet N, et al (1996). Osteopontin expression in lung cancer. Lung Cancer, 15, 311-23.
4. Furger KA, Allan AL, Wilson SM, et al (2003). Beta (3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res, 1, 810-9.
5. Gardner HA, Berse B, Senger DR (1994). Specific reduction in osteopontin synthesis by antisense rna inhibits the tumorigenicity of transformed rat1 fibroblasts. Oncogene, 9, 2321-6.
6. He B, Mirza M, Weber GF (2006). An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene, 25, 2192-202.
7. Hofstetter W, Swisher SG, Correa AM, et al (2002). Treatment outcomes of resected esophageal cancer. Ann Surg, 236, 376-84; discussion 84-5.
8. Ito T, Hashimoto Y, Tanaka E, et al (2006). An inducible shorthairpin rna vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo. Clin Cancer Res, 12, 1308-16.
9. Katagiri YU, Sleeman J, Fujii H, et al (1999). Cd44 variants but not cd44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginineglycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res, 59, 219-26.
10. Kita Y, Natsugoe S, Okumura H, et al (2006). Expression of osteopontin in oesophageal squamous cell carcinoma. Br J Cancer, 95, 634-8.
11. Lee JM, Wu MT, Lee YC, et al (2005). Association of gstp1 polymorphism and survival for esophageal cancer. Clin Cancer Res, 11, 4749-53.
12. Lin JY, Wang MS, Dong LP, et al (2012). Influence of personal character on quality of life of patients with esophageal cancer in north Henan province and influencing factors. Asian Pac J Cancer Prev, 13, 5415-20.
13. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative pcr and the 2 (-delta delta c (t)) method. Methods, 25, 402-8.
14. Ma JB, Chen EC, Song YP, et al (2013). Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma. Asian Pac J Cancer Prev, 14, 2477-81.
15. Mirza M, Shaughnessy E, Hurley JK, et al (2008). Osteopontin-c is a selective marker of breast cancer. Int J Cancer, 122, 889-97.
16. Schorge JO, Drake RD, Lee H, et al (2004). Osteopontin as an adjunct to ca125 in detecting recurrent ovarian cancer. Clin Cancer Res, 10, 3474-8.
17. Senger DR, Ledbetter SR, Claffey KP, et al (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol, 149, 293-305.
18. Sodek J, Ganss B, McKee MD (2000). Osteopontin. Crit Rev Oral Biol Med, 11, 279-303.
19. Thalmann GN, Sikes RA, Devoll RE, et al (1999). Osteopontin: Possible role in prostate cancer progression. Clin Cancer Res, 5, 2271-7.
20. Tuck AB, Chambers AF (2001). The role of osteopontin in breast cancer: Clinical and experimental studies. J Mammary Gland Biol Neoplasia, 6, 419-29.
21. Vizcaino AP, Moreno V, Lambert R, et al (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries. Int J Cancer, 99, 860-8.
22. Wang S, Liu H, Akhtar J, et al (2013). Alteration of runt-related transcription factor 3 gene expression and biologic behavior of esophageal carcinoma TE-1 cells after 5-azacytidine intervention. Asian Pac J Cancer Prev, 14, 5427-33.
23. Weber GF, Ashkar S, Glimcher MJ, et al (1996). Receptor-ligand interaction between cd44 and osteopontin (eta-1). Science, 271, 509-12.
24. Ye QH, Qin LX, Forgues M, et al (2003). Predicting hepatitis b virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 9, 416-23.